Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio

Genentech to present new data at ESMO across oncology portfolio including positive Phase III Krascendo 1 data in lung cancer ...